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A B S T R A C T
Introduction. Penile prosthesis infections have decreased since the introduction of antibiotic-coated implants.
Infections that do occur can be from more rare and virulent organisms than the traditional skin ﬂora historically
implicated.
Aim. In this report, we present two cases of inﬂatable penile prosthesis (IPP) infection from Candida organisms in
insulin-dependent diabetic patients.
Methods. Case report with literature review.
Main Outcome Measures. Resolution of the two cases.
Results. Both patients were found to have insulin-dependent diabetes. Both patients also presented with infection of
the device with Candida species, with the implant pump adherent to their scrotal skin.
Conclusions. This report supports the emerging literature that the ﬂora of IPP infections is changing. We suggest
considering adding antifungal agents to antibiotic coatings, dips, or washout solutions at the time of penile prosthesis
surgery in diabetic patients. Cotta BH, Butcher M, Welliver C, McVary K, and Köhler T. Two fungal infections
of inflatable penile prostheses in diabetics. Sex Med 2015;3:339–342.
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Introduction
S igniﬁcant progress has been made in inﬂatablepenile prosthesis (IPP) operations over the
years, with infections occurring in as little as 1% of
novel cases with the use of antibiotic-impregnated
implants in the hands of frequent implanters [1].
However, revision operations still have a higher
rate of infection, with studies citing 7–18% [2]. As
intravenous (IV) antibiotics are inadequate at
clearing the infection due to presence of a bioﬁlm,
any attempt at preventing infection is signiﬁcant.
Here we present two cases of IPP infections with
Candida, a common medical device pathogen but
one that is still very rarely encountered in penile
prosthesis operations.
Case Presentations
TW
TW was a 60-year-old male with insulin-
dependent type 2 diabetes (HbA1c 14.4%), obesity,
and sleep apnea presenting 6 months following
implantation of an AMS 700 3-piece inﬂatable
prosthesis complaining of difﬁculty inﬂating and
deﬂating the scrotal pump.
Because of extreme difﬁculty inﬂating the
device, the decisionwasmade to exchange the AMS
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pump with a Coloplast Touch pump, leaving the
remainder of the functional AMS implant in place.
Despite the potential increased risk of infection by
not exchanging the entire device, the patient opted
for pump component exchange only. Perioperative
antibiotics vancomycin and gentamicin were given
and a Mulcahy salvage procedure was performed
with a washout solution containing iodine, hydro-
gen peroxide, and antibiotics [3]. The original
pump and capsulewas entirely removed. A rifampin
and gentamicin Coloplast dip was utilized for the
newly implanted pump.
Postoperatively, the patient was able to cycle
his device successfully for intercourse. However,
4 months after the pump exchange operation, the
patient returned to the clinic complaining of iso-
lated pain in the area of pump placement and on
examination the pump was found to be ﬁxed to
the scrotum with localized erythema. A 10-day
course of TMP-SMX was attempted with no
improvement in symptoms. It was decided to
remove the entire device and replace it, with the
patient choosing to have a Coloplast Genesis
malleable implant. Perioperative gentamicin and
vancomycin were given within 1 hour of incision.
The surgical site was prepped with a combination
of chlorhexidine and alcohol [4] in addition to an
iodine-based skin cover to avoid skin contamina-
tion. When dissecting down into the area of the
pump within the scrotum, a purulent drainage
was noted and sent for culture. After complete
device removal, a Mulcahy washout procedure
was performed in the implant space containing
iodine, hydrogen peroxide, and antibiotic solu-
tions [3]. Results of the culture of the purulent
drainage and previous implant capsule obtained
from surgery grew Candida glabrata. The patient
experienced no complications postoperatively and
the device was functional with no signs of infec-
tion at any follow-up appointments, up to 1 year
at the time of publication.
MW
MW was a 52-year-old male with insulin-
dependent type 2 diabetes (HbA1c unknown),
hypertension, and dyslipidemia presenting for
consultation 2 years after implantation with a
Coloplast Titan 3-piece IPP. He complained of
scrotal pain and examination revealed localized
erythema and pump ﬁxation to the skin. Despite a
6-week course of TMP-SMX, the patient’s symp-
toms persisted and the area developed a draining
sinus tract in the anterior scrotum. A wound
culture grew Candida albicans. He then underwent
revision surgery and complete device replacement
with a Coloplast Genesis malleable device.
Perioperative vancomycin, ceftriaxone, and
ﬂuconazole were given. Upon entry into the
pump capsule, purulent drainage was noted. The
washout solution irrigated into the previous
implant spaces included iodine, hydrogen perox-
ide, vancomycin, gentamicin, and the addition of
ﬂuconazole to cover for the Candida grown from
the wound drainage cultured preoperatively. The
dip utilized for the malleable implant was a com-
bination of ﬂuconazole, rifampin, and gentamicin.
Culture of the drainage and capsule also grew
C. albicans. His postoperative course was unevent-
ful and he was doing well with no signs of infec-
tion at any of his follow-up appointments, his
most recent visit being 1 year postoperatively.
Discussion
Herewe present two cases of IPP component infec-
tions with Candida species. Both patients had a long
history of type 2 diabetes requiring insulin. Each
presentation was delayed, with TW experiencing
infectious complications 4 months after a pump
exchange and MW presenting 2 years after original
device placement. Both patients presented with
scrotal pain and displayed similar physical exam
ﬁndings of an implant component adhered to their
scrotal skin with erythema and no systemic signs of
infection. Not surprisingly, neither infection
responded to antibiotics despite recent literature
supporting success with this technique in
nonsystemic localized implant infections [5]. Of
note, these cases were the only two implant infec-
tions with “non-aggressive organisms” with classic,
historically described pump ﬁxation seen at our
institution over the last 7 years.
Fungal Device Infections
Candida infections are a common cause of medical
device infections, likely due to their ability to form
a bioﬁlm. As all humans are colonized with yeast as
a commensal organism, their virulence is related to
impairment of host defenses. The most common
conditions leading to overgrowth of Candida
include immunocompromised states, diabetes mel-
litus, antibiotic use, indwelling devices, and IVdrug
use [6]. Candida is responsible for less than 1% of
joint prosthesis infections, 2.6–7% of periotoneal
dialysis infections, 2–10% of prosthetic heart valve
infections, 4.5% of pacemaker infections, and 21%
of catheter-associated urinary tract infections [6].
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Candida is estimated to be responsible for 5–9% of
penile prosthesis infections in the nonantibiotic
device coated era [3] and most of these infections
are recorded in the literature as case reports [7].
Impact of Diabetes on IPP Infection Risk
It has long been known that diabetic patients are
more likely to suffer from infectious complications
after surgery. This increased risk may be due to
impaired host resistance, high blood glucose levels
promoting bacterial growth, and poor blood
supply to the wound. In fact, a long-term study
comparing IPP infection rates in diabetic and not
diabetic men found that diabetic men had a sig-
niﬁcantly higher rate of infection of the IPP at 7
years [8]. However, this increased risk is difﬁcult to
quantify. In a study tracking IPP infection rates in
patients with risk factors for infection, diabetes
was found to lead to a statistically insigniﬁcant
increase in initial implant infections (1% to 3%)
and an even larger increase in infections at revision
surgery (8% to 18%), but again not signiﬁcant [9].
Levels of diabetes control as quantiﬁed by
glycosylated hemoglobin (HbA1c) have also been
studied as a proxy measurement for IPP infection
risk. Bishop et al. initially reported a difference of
31% vs. 5% of implant infections in poorly con-
trolled diabetics deﬁned by a HbA1c level of
greater than 11.5% [10]. However, a similar study
performed by Wilson et al. found that while an
increased incidence of infections developed in dia-
betics (10 diabetics [8.8%] and 11 nondiabetics
[4.0%] [P = 0.06]), only one infection occurred
among poorly controlled diabetics, again deﬁned
by HbA1c levels above 11.5% [11]. Additionally,
no difference was found among diabetics when
stratifying them further by level of preoperative
fasting glucose or insulin dependence. Additional
factors not studied that could explain the increased
rate of infection independent of glucose control
may be duration of diabetes and the associated
vascular changes in these patients [11]. Due to
conﬂicting reports and the fact that these studies
were done prior to the evolution of antibiotic-
impregnated implants, it may be time to restudy
diabetes control as a risk factor for IPP infections,
particularly in rare cases of opportunistic infec-
tions such as the fungal infections we report.
Antibiotic Coated Implants: Are We Selecting for
More Virulent Organisms?
The source of microbes causing implant infections
is most commonly skin ﬂora, as seen in most pros-
thetic device infections. This was especially true in
IPP infections before the widespread use of
antibiotic-coated implants, where up to 75% of
device infected were due to coagulase negative
Staphylococcus [12]. However, there is increasing
evidence that the ﬂora of IPP infections is chang-
ing. Kava et al. cultured tissue from implant spaces
at the time of revision surgery and found that only
5% contained Staphylococcus epidermidis [13]. Addi-
tionally, of the small number of cases revised for
infectious reasons, the infecting organism was
Staphylococcus aureus in half of cases and none was
due to coagulase negative Staphylococcus. The
second most common infecting organism was
Enterobacter aerogenes [13]. Furthermore, case
reports of IPP infections with rare organisms such
as Salmonella [14] and Actinomyces neuii [15] have
surfaced. Antibiotic use has been proven to be the
number one risk factor contributing to Candida
infections [16]; therefore, it is reasonable to assume
that antibiotic coatings and prophylactic antibiotics
in our prosthetic patients may open the door for
these commensal organisms to become pathogens.
Future Considerations
Since their introduction in the early 2000s, infec-
tion retardant coatings on IPPs have dramatically
decreased device infections, such that recent evi-
dence indicates that the most common reason for
device failure may now be mechanical [17].
However, of those infections that do occur, the
microbial ﬂora may become increasingly more
virulent. For this reason, the traditional antibiot-
ics, originally tested for their ability to combat
common skin organisms, may become less efﬁca-
cious over time. Recent reports of atypical infec-
tions of IPPs and our experience of two Candida
infections in a short (one month) time period may
provide incentive for adding antifungal medica-
tions to perioperative administration protocols,
antibiotic dips, and washout solutions. As both of
our patients were also diabetic, further identifying
risk factors in patients for device infection and
further establishing the risk of diabetic control on
this vulnerable population are also warranted.
Conclusion
Penile prosthesis implantations have become
increasingly successful in their near 40 years of use.
With a markedly reduced number of infections in
primary implantations and further reduction in
revision infections with the use antibiotic-coated
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implants and washout procedures, most surgeons
experience relatively few infectious complications.
However, when the rare infection occurs, we may
become victims of our own success by selecting
for potentially more virulent or nontargeted
organisms.
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